|
Drug abuse
|
0.300 |
Biomarker
|
group |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Drug habituation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Drug Use Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Organic Mental Disorders, Substance-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Substance Dependence
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Substance Use Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Substance-Related Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Substance abuse problem
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Drug Dependence
|
0.300 |
Biomarker
|
group |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Prescription Drug Abuse
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary spontaneous pneumothorax (PSP) generally occurs in young adults, whereas pediatric PSP is uncommon.
|
30955098 |
2019 |
|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Objectives:</b> The present study is geared to learning about the patterns of tau seeding and cells involved following unilateral inoculation in the corpus callosum of homogenates from sporadic Alzheimer's disease (AD), primary age-related tauopathy (PART: neuronal 4Rtau and 3Rtau), pure aging-related tau astrogliopathy (ARTAG: astroglial 4Rtau with thorn-shaped astrocytes TSAs), globular glial tauopathy (GGT: 4Rtau with neuronal tau and specific tau inclusions in astrocytes and oligodendrocytes, GAIs and GOIs, respectively), progressive supranuclear palsy (PSP: 4Rtau with neuronal inclusions, tufted astrocytes and coiled bodies), Pick's disease (PiD: 3Rtau with characteristic Pick bodies in neurons and tau containing fibrillar astrocytes), and frontotemporal lobar degeneration linked to P301L mutation (FTLD-P301L: 4Rtau familial tauopathy).
|
31191295 |
2019 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The overall sensitivity of the International Parkinson and Movement Disorder Society criteria was 87.9%, compared with 45.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria, whereas the specificity of the International Parkinson and Movement Disorder Society probable PSP criteria was 85.7%, compared with 90.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy.
|
30726566 |
2019 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present a series of patients with vertical supranuclear gaze palsy, postural instability with falls, and progressive spasticity, who mimic Progressive Supranuclear Palsy - Richardson's syndrome (PSP-R) but have no parkinsonism, and in whom dopamine transporter imaging is normal.
|
29801913 |
2018 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differentiating clinically progressive supranuclear palsy-parkinsonism (PSP-P) from Parkinson's disease (PD) may be challenging, especially in the absence of vertical supranuclear gaze palsy (VSGP).
|
30068492 |
2018 |
|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This is, to best of our knowledge, the first report describing a pathologically confirmed progressive supranuclear palsy - corticobasal syndrome (PSP-CBS) variant case in a <i>FMR1</i> premutation carrier.
|
30158953 |
2018 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further studies on earlier stage non-demented PSP patients are required to ascertain whether stereotypies are characteristic of PSP in general or are confined to PSP-RS, and whether they may be used to suggest a PSP diagnosis early in disease course.
|
30399478 |
2018 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The differentiation of progressive supranuclear palsy-parkinsonism (PSP-P) from Parkinson's disease (PD) remains a major clinical challenge.
|
29463454 |
2018 |
|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to assess whether a combined analysis of dopamine transporter (DAT)- and perfusion-SPECT images (or either) could: (1) distinguish atypical parkinsonian syndromes (APS) from Lewy body diseases (LBD; majority Parkinson disease [PD]), and (2) differentiate among APS subgroups (progressive supranuclear palsy [PSP], corticobasal syndrome [CBS], and multiple system atrophy [MSA]).
|
29157745 |
2018 |
|
Suntan
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association study in 176,678 Europeans reveals genetic loci for tanning response to sun exposure.
|
29739929 |
2018 |
|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Progressive supranuclear palsy syndrome (PSP-S) results from neurodegeneration within a network of brainstem, subcortical, frontal and parietal cortical brain regions.
|
28951832 |
2017 |
|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP, have excellent specificity, but their sensitivity is limited for variant PSP syndromes with presentations other than Richardson's syndrome.
|
28467028 |
2017 |
|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To elucidate different patterns of progression of midbrain atrophy in patients with Richardson's syndrome (RS), progressive supranuclear palsy-parkinsonism (PSP-P), and Parkinson's disease (PD) using magnetic resonance imaging (MRI)-based visual rating indexes.
|
27614955 |
2017 |
|
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
We define a five-level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group-level findings, level 2 representing biomarkers with demonstrable individual-level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology.
|
28500751 |
2017 |
|
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rs186977284 was also present in 2.7% of a large cohort of autopsy-confirmed PSP patients (N = 566) and only 0.9% of an additional control series (P = 0.034, OR = 3.08), extending the association to PSP.
|
24121548 |
2014 |